1. Home
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Gastrointestinal Stromal Tumor (GIST) - Epidemiology Forecast - 2032

Gastrointestinal Stromal Tumor (GIST) - Epidemiology Forecast - 2032

  • August 2022
  • 100 pages
  • ID: 6316461
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

DelveInsight’s Gastrointestinal Stromal Tumor (GIST)- Epidemiology Forecast–2032’ report delivers an in-depth understanding of the Gastrointestinal Stromal Tumor (GIST), historical and forecasted epidemiology as well as the Gastrointestinal Stromal Tumor (GIST) trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Gastrointestinal Stromal Tumor (GIST) Disease Understanding
As per GIST Support International, gastrointestinal stromal tumor (GIST) is rare cancer affecting the digestive tract or nearby structures within the abdomen. It is a sarcoma that arises either from cells called interstitial cells of Cajal (ICCs) or from less differentiated stem cells or precursor cells that can develop into ICCs.
GIST progression is driven by mutations in KIT or PDGFRA or by other rare gene alterations, all of which are mutually exclusive. It is known that the majority of tumors of GIST will have mutations in the KIT gene, and a minority, in the PDGFR gene.
Wild-type GIST do not have mutations of the KIT or PDGFR genes. Some of the cases of wild-type GIST have been linked to genes involved in the succinate dehydrogenase (SDH) enzyme complex (i.e., SDHA, SDHB, SDHC, or SDHD genes). Additional genes have been linked to wild-type GIST, includes BRAF, KRAS, and NRAS mutations.
Gastrointestinal Stromal Tumor (GIST) Diagnosis
A GIST diagnosis is typically made or ruled out based on a patient’s medical history, a comprehensive physical examination, and the results of a series of tests. The testing methods used to confirm or rule out a GIST can vary based on a patient’s symptoms and other individual factors.
After physical examination, CT scan (CAT scan), MRI, Endoscopic ultrasound, biopsy, Immunohistochemistry, Mitotic rate, PET scan can be performed to confirm the disease and its severity.
Continued in the report…..
Gastrointestinal Stromal Tumor (GIST) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total incident cases of GIST, Gender-specific Incident Cases of GIST, Age-specific Incident Cases of GIST, Incident Cases of GIST by Mutation, and Stage-specific Incident Cases of GIST in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2032.
Gastrointestinal Stromal Tumor (GIST) Detailed Epidemiology Segmentation
• In the assessment done , the estimated total incident cases of GIST in the 7MM were 14,251 in 2021.
• The highest incident cases of GIST were accounted by the US in 2021 (6,035 cases), which are expected to show a steep rise soon due to the improvement in diagnostic testing and advancements in genetic testing and accounts for 42% of the total cases in the 7MM.
• In 2021, the age-specific incident cases of GIST accounted highest in the age group 66-80 years with 5,384 cases in the 7MM, followed by age group 51-65 years with 4,581 cases. While the least number of cases were seen in the age group 0-17 years.
• Among the European countries, Germany had the highest incident population of GIST with 1,736 cases, followed by Italy, which had incident population of 1,095 in 2021. On the other hand, Spain had the lowest incident population (824 cases).
• Japan had 2,458 incident cases for GIST in 2021, accounting for approximately 17% of total incident cases in the 7MM.

Scope of the Report
• The report covers the descriptive overview of Gastrointestinal Stromal Tumor (GIST), explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden of Gastrointestinal Stromal Tumor (GIST).
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

Report Highlights
• 11-Year Forecast of Gastrointestinal Stromal Tumor (GIST)
• 7MM Coverage
• Total Incident Cases of GIST
• Gender-specific Incident Cases of GIST
• Age-specific Incident Cases of GIST
• Mutation-specific Incident Cases of GIST
• Stage-specific Incident Cases of GIST

Key Questions Answered
• What are the disease risk and burden of Gastrointestinal Stromal Tumor (GIST)?
• What is the historical Gastrointestinal Stromal Tumor (GIST) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Gastrointestinal Stromal Tumor (GIST) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Gastrointestinal Stromal Tumor (GIST)?
• Out of the above-mentioned countries, which country would have the highest incident population of Gastrointestinal Stromal Tumor (GIST) during the forecast period (2022–2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

Reasons to buy
The Gastrointestinal Stromal Tumor (GIST) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Gastrointestinal Stromal Tumor (GIST) epidemiology forecast.
• The Gastrointestinal Stromal Tumor (GIST) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Gastrointestinal Stromal Tumor (GIST) epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2019–2032

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Castleman Disease Treatment Market Research Report by Disease Type, Indication, Therapy, Application, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

  • $ 3949
  • January 2023
  • 145 pages

Castleman Disease Treatment Market Research Report by Disease Type (Multicentric Castleman’s Disease and Unicentric Castleman’s Disease), Indication, Therapy, Application, State - Cumulative Impact ...

  • United States
  • Antiviral
  • Marketing Research
  • Industry analysis

ref:plp2022

Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on